Lyell Immunopharma, a South San Francisco-based publicly traded cell therapy company (LYEL), focuses on T cell reprogramming technology to treat patients with solid tumors. Using proprietary genetic and epigenetic platforms, Lyell aims to overcome barriers in solid tumors and develop medicines with durable, potentially curative outcomes. As a cloud-first organization, most of its operations rely on cloud services for generating and storing proprietary data. Operating in a highly regulated biotechnology environment, Lyell needed a solution that ensures robust security for hosts, networks, and cloud infrastructure while meeting stringent compliance requirements.

Join for free to read